South African MedTech Breakthrough Achieves Landmark First Human Use in United States Surgical Procedures

South African firm Strait Access Technologies achieves first human use of its CenterFlow catheter in the US, revolutionizing aortic aneurysm repair safety.

By: AXL Media

Published: Mar 24, 2026, 4:33 AM EDT

Source: The information in this article was sourced from Engineering News

A Critical Advancement in Cardiovascular Surgical Precision

The global medical technology landscape witnessed a significant shift as Strait Access Technologies, a firm originating from the University of Cape Town, announced the successful maiden human application of its CenterFlow balloon dilation catheter. Conducted at two premier American institutions, Massachusetts General Hospital and Jefferson University Hospital, these procedures mark the commercial realization of nearly a decade of South African engineering. The device addresses a long-standing volatility in vascular surgery by stabilizing the environment during the delicate process of moulding repair sleeves within the aorta.

Overcoming the Risks of Conventional Aortic Arterial Repair

Traditional methods for repairing the body’s largest artery have historically been hampered by the physiological necessity of blocking blood flow to secure repair devices. According to technical specifications, standard balloons create a high-risk stasis that leaves surgeons with only seconds to complete critical adjustments before potential organ damage occurs. The newly deployed technology utilizes a hollow-core design, which ensures that circulation remains uninterrupted even while the balloon is fully inflated. This structural innovation effectively transforms a high-pressure, seconds-long window into a manageable multi-minute timeframe.

The Strategic Path from Academic Research to FDA Clearance

The journey of the CenterFlow device from a University of Cape Town laboratory to operating theaters in the United States spanned nine years of rigorous development and clinical testing. Co-developers Dr Roman Gottardi and Dr Martin Czerny worked alongside founder Dr Peter Zilla to secure the necessary regulatory milestones, culminating in a 510(k) clearance from the US Food and Drug Administration. This regulatory approval not only permits immediate commercial use in the world’s largest healthcare market but also validates the sophisticated nature of South African biomedical research on an international stage.